News Releases

News & Events

News Releases

Synteract’s Head of Pediatric Development to Present at Better Medicines for Children Conference, Belgium

RESEARCH TRIANGLE PARK, NC– Oct. 22, 2018Synteract, an innovative CRO partnering with biotech and pharma companies to bring new medicines to market, is announcing its Vice President of Pediatric Development, Dr. Martine Dehlinger-Kremer will be kicking off and presenting at the EFGCP & DIA Better Medicines for Children Conference, October 25-26, 2018 in Brussels, Belgium.

Dr. Dehlinger-Kremer is at the forefront of pediatric drug development, as she heads up this center of development for Synteract, while also serving as chair of the Pediatric Working Group of EUCROF, chair of the EFGCP Children Medicines Working Party, an observer member of the Coordinating Group of Enpr-EMA, and president of EUCROF.

Her schedule at the conference includes: 

  • Thursday, October 25
    • 8:30 a.m. - Dr. Dehlinger-Kremer will kick off the event alongside Chair of the EMA, Dr. Dirk Mentzer.
    • 11:15 a.m. - Dr. Dehlinger-Kremer will serve on a “Meet the Expert” session on “Enabling Access for Different Pediatric Populations” (BOS 2) on neonates.
    • 1:15 p.m. - Dr. Dehlinger-Kremer will co-chair a lunch Q&A “Access Through Approval” session with Dr. Mentzer on “View of the Regulators.”
  • Friday, October 26
    • 3:30 p.m. - Dr. Dehlinger-Kremer and Dr. Mentzer will wrap up the conference.

Synteract has a long history of pediatric clinical trial expertise across all phases of drug development, with close to 100 projects across a broad range of indications. It specializes in helping sponsors navigate the complexities of research related to children and adolescents with tailored pediatric development planning and experienced operational support to allow medicines to reach patients in need.

“Better Medicines for Children…From Development to Access” is the focus of the event this year, jointly organized by EFGCP and DIA. It will take stock of progress achieved after 10 years of pediatric regulation and move the discussion toward the experience of patients. All stakeholders involved in the process, from research through treatment of childhood diseases, including patients, as well as HTA and payers, are invited to share updates in the field and discuss challenges to access new medicines.

Interested in meeting with Synteract at Better Medicines for Children or after the event to discuss emerging strategies in pediatric drug development? Contact us today.

About Synteract
With 800 employees across 21 countries, Synteract is an innovative CRO supporting biotech and pharma companies across all phases of drug development to help bring new medicines to market. Synteract has conducted nearly 4,000 studies on six continents and in more than 60 countries, working with more than 26,000 investigative sites and nearly 750,000 patients. It has contributed to more than 240 product approvals. Synteract offers a notable depth of therapeutic expertise in oncology, dermatology, neuro degenerative, as well as pediatrics and rare and orphan.

Connect on LinkedIn and Twitter.

# # #
Hilary McCarthy


Contact Synteract

Tell us how to stay in touch with you: